Detection of Atrial Fibrillation in Different Patient Target Groups Using the FibriCheck Smartphone Application

NCT ID: NCT03509493

Last Updated: 2018-04-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

465 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-06-01

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

FibriCheck is a Conformité Européenne (CE)-approved (class IIa) medically diagnostic application that allows for heart rhythm registrations based on an optical signal captured via the smartphone camera. FibriCheck is only available on prescription causing the physician to stay in the 'driving seat' and the application distribution to be traced.

By using FibriCheck, a medically validated smartphone application, daily rhythm measurements can be performed using only the smartphone of the patient. This allows for the heart rhythm to be registered and monitored in a home environment and the data to be automatically sent to the physician. This enables the implementation of FibriCheck in two types of scenarios:

* Scenario 1: the follow-up of patients with high risk parameters for AF development for primary and secondary prevention, whereby detection of AF will result in therapeutic intervention
* Scenario 2: the realisation of monitoring of the heart rhythm of patients post intervention in a home environment

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Atrial fibrillation (AF) is the most common heart rhythm disorder affecting 50 million people in Europe and the U.S. It is associated with an increasing mortality and risk for transient cerebrovascular incidents and dementia. De novo AF is in most cases asymptomatic and paroxysmal, causing the diagnosis to be made either by chance or in response to an incident. This drastically impacts the quality of life of the patient and is accompanied with a high socio-economic cost. Guidelines indicate that anticoagulation in patients diagnosed with AF is a cost-effective solution for the prevention of strokes.

In addition, depending on the target group, patients identified with AF can receive therapy in order to control the heart rhythm. These procedures (cardioversion and ablation) often result in follow-up consultations that can be avoided if the heart rhythm can be monitored remotely.

By using FibriCheck, a medically validated smartphone application, daily rhythm measurements can be performed using only the smartphone of the patient. This allows for the heart rhythm to be registered and monitored in a home environment and the data to be automatically sent to the physician. This enables the implementation of FibriCheck in two types of scenarios:

* Scenario 1: the follow-up of patients with high risk parameters for AF development for primary and secondary prevention, whereby detection of AF will result in therapeutic intervention
* Scenario 2: the realisation of monitoring of the heart rhythm of patients post intervention in a home environment

The follow-up of patients is still driven by the treating physician(s). The objective is to implement a correct and successful process management allowing a smooth implementation of "an application on prescription".

Short- and long-term benefits the project wants to prove:

Short-term:

\- AF can successfully be detected in a home environment using the FibriCheck application

Long-term: a successful detection of AF in a home environment can:

* Be the first step towards changing and improving the care pathway of the patient
* Induce therapeutic interventions in order to prevent strokes or other complications

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Primary prevention Secondary prevention Clinical practice

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients without structural heart disease

FibriCheck

Intervention Type DIAGNOSTIC_TEST

Digital health application

Patients with structural heart disease

FibriCheck

Intervention Type DIAGNOSTIC_TEST

Digital health application

Patients with high risk parameters for AF development

FibriCheck

Intervention Type DIAGNOSTIC_TEST

Digital health application

Patients post-cryptogenic stroke

FibriCheck

Intervention Type DIAGNOSTIC_TEST

Digital health application

Patients post-cardioversion therapy

FibriCheck

Intervention Type DIAGNOSTIC_TEST

Digital health application

Patients post-ablation therapy

FibriCheck

Intervention Type DIAGNOSTIC_TEST

Digital health application

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FibriCheck

Digital health application

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Group 1: Patients without structural heart disease

* Age 65 and older
* CHADSVASc score of 2 or more (including congestive heart failure, hypertension, age, diabetes, previous stroke, vascular disease and sex)
* Comorbidities such as: coronary artery disease, kidney insufficiency, sleep apnea or symptomatic complaints with negative Holter in the past

Group 2: Patients with structural heart disease

* Age 65 and older
* CHADSVASc score of 2 or more
* Left atrial volume indexed for body surface area (BSA) of 34 ml/m² or more, or left atrial diameter \> 5 cm
* And any of the following indicators:

* Diastolic dysfunction of at least grade 2 with restrictive filling (E/A 2 or more) or disturbed relaxation (E/A 0.8) and with E/e' septal 15 or more (E/e' lateral 10 or more) or tricuspid insufficiency (TI) of 2.8 m/s or more
* At least mitral insufficiency (grade 2/3 or 3/3) or mitral stenosis
* Hypertrophic (obstructive) cardiomyopathy

Group 3: Patients with high risk parameters for AF development

* Age 65 or more
* General Medical Record in the participating practice
* A 5-year risk of AF of at least 10% according to the CHARGE-AF risk score

Group 4: Patients post-cryptogenic stroke or TIA

\- Experienced a cryptogenic TIA or stroke in the past year since the start of the study

Group 5: Patients post-cardioversion therapy

* Confirmed AF patient based on 12-lead ECG
* Successful AF treatment using cardioversion (DCC or chemical) to convert the heart rhythm back to normal sinus rhythm
* Subjects are older than 18 years

Group 6: Patients post-ablation therapy

* Confirmed AF patient based on 12-lead ECG
* Successful AF treatment using ablation therapy to restore the heart rhythm back to sinus rhythm in the past 3 months
* Subjects are older than 18 years

Exclusion Criteria

* Non-native Dutch
* Pacemaker dependent heart rhythm
* Perniosis patient
* Intense callus formation
* Low adherence to protocol
* Tremor or Parkinson
* Signs of Alzheimer or dementia
* No self-care ability
* Known AF patient
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Qompium NV

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ziekenhuis Oost Limburg

Genk, Limburg, Belgium

Site Status

Jessa Ziekenhuis

Hasselt, Limburg, Belgium

Site Status

AZ Maria Middelares

Ghent, Oost-Vlaanderen, Belgium

Site Status

AC Huisartsengeneeskunde KU Leuven

Leuven, Vlaams-Brabant, Belgium

Site Status

HAK Hooglede

Hooglede, West-Vlaanderen, Belgium

Site Status

Jan Yperman Ziekenhuis

Ieper, West-Vlaanderen, Belgium

Site Status

AZ Groeninge

Kortrijk, West-Vlaanderen, Belgium

Site Status

AZ Delta Ziekenhuis

Roeselare, West-Vlaanderen, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

References

Explore related publications, articles, or registry entries linked to this study.

Beerten SG, Proesmans T, Vaes B. A Heart Rate Monitoring App (FibriCheck) for Atrial Fibrillation in General Practice: Pilot Usability Study. JMIR Form Res. 2021 Apr 7;5(4):e24461. doi: 10.2196/24461.

Reference Type DERIVED
PMID: 33825692 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1

Identifier Type: -

Identifier Source: org_study_id